NETHERLANDS

Technip Energies convenes its 2024 Annual General Meeting

Retrieved on: 
Tuesday, March 26, 2024
Annual report, AGM, Engineering & Technology, Energy

Technip Energies (PARIS:TE) (the “Company”), a leading Engineering & Technology company for the energy transition, today announces the publication of the Convening Notice for its Annual General Meeting (AGM), which will be held on May 7, 2024, at 2:00 p.m. CEST in Schiphol, the Netherlands.

Key Points: 
  • Technip Energies (PARIS:TE) (the “Company”), a leading Engineering & Technology company for the energy transition, today announces the publication of the Convening Notice for its Annual General Meeting (AGM), which will be held on May 7, 2024, at 2:00 p.m. CEST in Schiphol, the Netherlands.
  • The Convening Notice, agenda and explanatory notes, as well as other relevant meeting documents are available at: https://investors.technipenergies.com/news-events/agm
    The Company’s 2023 Annual Report is available at:

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Blood pressure, Efgartigimod alfa, System, Urination, Urinary tract infection, MHLW, Chest pain, Rituximab, Allergy, Disease, Infection, Risk, Headache, Patient, Sore throat, IWG, History, ITP, Chills, Quality of life, Cough, Euronext, Rash, Respiratory tract infection, Splenectomy, Medicine, Skin, Fever, Antibody, Wheeze, Back pain, Shivering, Safety, Pain, Fatigue, Phlegm, Swelling, Food, Autoimmune disease, Nursing

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.

Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2

Retrieved on: 
Tuesday, March 26, 2024
Conference, Immunoglobulin A, Female, Aes, FIH, SARS-CoV-2, Volunteering, Trial of the century, Male, OMV, Vaccination, Safety, Vaccine, Immunoglobulin G, Administration

The phase I clinical trial, which was conducted in Australia, assessed the tolerability, safety and immunogenicity of the Avacc 10® vaccine.

Key Points: 
  • The phase I clinical trial, which was conducted in Australia, assessed the tolerability, safety and immunogenicity of the Avacc 10® vaccine.
  • In a randomized, double-blinded, placebo and OMV controlled study, 36 healthy 18-55 year-old, male and female volunteers, received two intranasal doses, 3 weeks apart.
  • Dr. Dinja Oosterhoff, Intravacc’s VP of Research & Development, stated:
    “This FIH intranasal vaccine study marks a significant milestone for Intravacc’s flagship OMV based vaccine platform.
  • Now Intravacc is also developing an intranasal vaccine for Gonorrhea targeting the FIH in Q4 2025.

Grafana Labs Unveiled Open Source Project Updates at Annual GrafanaCON Community Conference

Retrieved on: 
Tuesday, April 9, 2024
Professional Services, Data Management, Technology, Data Analytics, Software, Networks, Loki, Cloud, Metric, Radiation, Organization, Plant, Growth, Data science, Entrepreneurship, Science, JAXA, Moon, Integration, Tempo, SLIM, Anomaly, GitHub, Acceleration, SAML, Data, Metadata, Ecosystem, ID, UI, Video game

Grafana Labs, the company behind the world’s most ubiquitous, open and composable operational dashboards, today made three major announcements that build on its commitment to the open source community: the release of Grafana 11.0, Loki 3.0, and Grafana Alloy – the company's open source distribution of the OpenTelemetry Collector.

Key Points: 
  • Grafana Labs, the company behind the world’s most ubiquitous, open and composable operational dashboards, today made three major announcements that build on its commitment to the open source community: the release of Grafana 11.0, Loki 3.0, and Grafana Alloy – the company's open source distribution of the OpenTelemetry Collector.
  • These updates were unveiled during Grafana Labs’ sold-out GrafanaCON community conference in Amsterdam, held in person for the first time in five years.
  • GrafanaCON, originally centered solely on the Grafana project, has evolved this year to include the extended open source observability ecosystem.
  • During the keynote, Grafana Labs CEO Raj Dutt presented the second annual Golden Grot Awards , which recognize dashboards created by community members.

Europe Furniture Retailing Report 2024, with 175 Company Profiles including DFS, Fournier, IKEA, John Lewis, La Redoute, Migros, Poltronesofa, Segmuller, Wayfair, Furniture Village, Nobia and More - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 9, 2024
Retail, Home Goods, Furniture, Growth, DIY, Acquisition, Acceleration

The European furniture retailing market is a EUR 165 billion market.

Key Points: 
  • The European furniture retailing market is a EUR 165 billion market.
  • The market exhibited robust growth in 2021, followed by a deceleration in 2022, and a contraction in 2023.
  • Significant mergers, acquisitions, and agreements that occurred in the last 5 years among leading furniture retailers are also provided.
  • Over 760 furniture retailers and buying groups, of which 175 with detailed profiles are mentioned in the study.

Universal Robots Expands Partnership with MathWorks by Joining Connections Program

Retrieved on: 
Tuesday, April 9, 2024
Hardware, Electronic Design Automation, Semiconductor, Automotive Manufacturing, Aerospace, Data Management, Manufacturing, Technology, Robotics, Artificial Intelligence, Machinery, Software, Machine Tools, Metalworking & Metallurgy, Networks, Mobile, Wireless, Automation, Autonomous robot, Organization, MathWorks, Partnership, MATLAB, Universal Robots, ARM, UR, RoboCup, Student, Universal, Simulink, Multimedia, Robot, Computer data storage

Universal Robots , the Danish collaborative robot (cobot) company, has further strengthened its partnership with MathWorks, the leading developer of mathematical computing software, by joining the Mathworks Connections Program .

Key Points: 
  • Universal Robots , the Danish collaborative robot (cobot) company, has further strengthened its partnership with MathWorks, the leading developer of mathematical computing software, by joining the Mathworks Connections Program .
  • "In conjunction with MathWorks joining UR+ , Universal Robots’ entry into the Connections Program formalizes the organizations’ commitment to helping engineers develop advanced cobot applications and ensures compatibility with new MathWorks releases,” said Jim Tung, MathWorks Fellow.
  • Jesper Kildegaard Poulsen, Senior Director of Digital Ecosystems at Universal Robots, said, "We are delighted to be a part of the Connections Program and to expand our collaboration with MathWorks.
  • For information on the integrated offering from MathWorks and Universal Robots, visit Universal Robots’ Connections Page .

World Kitchen Furniture Market Outlook 2024, Featuring 35 Company Profiles Including American Woodmark, Boffi, Cabico, Hanssem, IKEA, Interwood, Nobia, Oppein, Scavolini, Schuller, Weizter and Zbom - ResearchAndMarkets.com

Retrieved on: 
Monday, April 8, 2024
Home Goods, Other Retail, Other Manufacturing, Specialty, Luxury, Discount, Variety, Manufacturing, Retail, Comparison, Chapter Two, Real, Chapter Three, Policy, Table, Statistics, Chapter One, GDP, USD, European, Cabinetry

World consumption of kitchen furniture is worth about USD 60 billion, accounting for about 15% of total world furniture consumption.

Key Points: 
  • World consumption of kitchen furniture is worth about USD 60 billion, accounting for about 15% of total world furniture consumption.
  • North America is the main consuming area, covering over one-third of the world's kitchen furniture market, followed by Europe and Asia Pacific.
  • Part 3: Company profiles provides company profiles for 35 among the main kitchen furniture manufacturers worldwide.
  • The 60 countries covered by the World Indicators of kitchen furniture were selected based on size of the economy, importance of the kitchen sector and contribution to world trade of kitchen furniture.

AACR 2024: PDC*line Pharma Presents Interim Clinical Results From Last Cohort of Patients in Phase I/II Trial with PDC*lung01 Cancer Vaccine

Retrieved on: 
Monday, April 8, 2024
Stem Cells, Biotechnology, Health, Pharmaceutical, Biometrics, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, KU Leuven, Mutation, Database, Survival, Best, DCR, Patient, Data, Aes, Șaeș, Progression-free survival, AACR, Kaplan–Meier estimator, Clinical trial, Cancer, Injection, ESMO, Safety, Symantec Endpoint Protection, DSMB, Poster, PFS, Vaccine, PDC

PDC*lung01 is the company’s off-the shelf therapeutic cancer vaccine candidate for Non-Small Cell Lung Cancer (NSCLC).

Key Points: 
  • PDC*lung01 is the company’s off-the shelf therapeutic cancer vaccine candidate for Non-Small Cell Lung Cancer (NSCLC).
  • The phase I/II trial (PDC-LUNG-101) aimed to assess the safety, tolerability, immunogenicity and preliminary clinical activity of PDC*lung01 in NSCLC patients, alone or in combination with anti-PD-1 treatment.
  • PDC*Line is reporting preliminary efficacy results for 19 evaluable patients in the B2 cohort that reached the 9-month PFS mark.
  • The final analysis of the clinical trial including the 45 patients from the B2 cohort will be conducted in Q3, 2024.

CyberCube Continues International Growth with Signing of First Insurance Broker in the Netherlands

Retrieved on: 
Monday, April 8, 2024
Technology, Insurance, Security, Professional Services, Software, Networks, Internet, Data Analytics, Data Management, Partnership, Senior, Education, Meijers, Growth, Risk management

Meijers Assurantiën , a Dutch insurance broker and Worldwide Broker Network member, has become CyberCube’s first client in the Netherlands marking the leading cyber risk modeler’s continued international expansion.

Key Points: 
  • Meijers Assurantiën , a Dutch insurance broker and Worldwide Broker Network member, has become CyberCube’s first client in the Netherlands marking the leading cyber risk modeler’s continued international expansion.
  • Meijers is a family business that has grown in half a century to become one of the largest independent insurance brokers in the Netherlands with approximately 450 employees.
  • Emma Drouineau, Sales Manager at CyberCube, said: “We are delighted Meijers has chosen CyberCube’s Broking Manager to enhance its cyber risk offerings.
  • CyberCube has customers globally and its analytics are now used by 11 of the top 20 global insurance brokers.

Hartwig and Ultima Genomics Collaborate to Reduce Costs for Whole Genome Cancer Profiling, Minimal Residual Disease Testing and Generating Genetic Data at Scale

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Medical Devices, Health, Genetics, Oncology, Database, Genetic testing, Disease, Patient, NGS, Research, Cancer, Ultima, Architecture, MRD, Medical foundation, Hartwig, Blood, SNV, Medical imaging

This collaboration aims to reduce test costs and make complete genome-based cancer diagnostics accessible for more patients to have better informed cancer treatment.

Key Points: 
  • This collaboration aims to reduce test costs and make complete genome-based cancer diagnostics accessible for more patients to have better informed cancer treatment.
  • In parallel, platform strengths will be explored for minimal residual disease detection in blood of cancer patients with a one-size-fits-all solution that builds on pre-existing complete tumor profile information.
  • “Collaborating with Hartwig to deploy our technology toward whole genome cancer profiling, MRD testing and generating genomic information at scale is an exciting milestone,” said Gilad Almogy, CEO of Ultima Genomics.
  • Furthermore, lower costs can enable Hartwig to affordably create genetic datasets at national population scale to improve cancer research and ultimately outcomes for future patients.